« Previous
Next »
Titles
- Searching for savings in Medicare drug price negotiations1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- State Pharmacy Assistance Programs vs. Medicare prescription drug plans: how do they contain rising costs?1
- State biosimilar substitution laws could reduce consumer access and savings1
- Strategic analysis & intelligence (SAI) report: the tier 4 phenomenon : shifting the high cost of drugs to consumers1